Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody

Yuki Katoh,1,2 Tomonori Yaguchi,1 Akiko Kubo,3 Takashi Iwata,1,4 Kenji Morii,1 Daiki Kato,1,5 Shigeki Ohta,1 Ryosuke Satomi,6 Yasuhiro Yamamoto,7 Yoshitaka Oyamada,6 Kota Ouchi,8,9 Shin Takahashi,8,9 Chikashi Ishioka,8,9 Ryo Matoba,10 Makoto Suematsu,3 Yutaka Kawakami1,11

ABSTRACT

Background Understanding the mechanisms of non-T cell inflamed tumor microenvironment (TME) and their modulation are important to improve cancer immunotherapies such as immune checkpoint inhibitors. The involvement of various immunometabolisms has recently been indicated in the formation of immunosuppressive TME. In this study, we investigated the immunological roles of stearoyl-CoA desaturase 1 (SCD1), which is essential for fatty acid metabolism, in the cancer immune response.

Methods We investigated the roles of SCD1 by inhibition with the chemical inhibitor or genetic manipulation in antitumor T cell responses and the therapeutic effect of anti-programmed cell death protein 1 (anti-PD-1) antibody using various mouse tumor models, and their cellular and molecular mechanisms. The roles of SCD1 in human cancers were also investigated by gene expression analyses of colon cancer tissues and by evaluating the related free fatty acids in sera obtained from patients with non-small cell lung cancer who were treated with anti-PD-1 antibody.

Results Systemic administration of a SCD1 inhibitor in mouse tumor models enhanced production of CCL4 by cancer cells through reduction of Wnt/β-catenin signaling and by CD8+ effector T cells through reduction of endoplasmic reticulum stress. In turn promoted recruitment of dendritic cells (DCs) into the tumors and enhanced the subsequent induction and tumor accumulation of antitumor CD8+ T cells. SCD1 inhibitor was also found to directly stimulate DCs and CD8+ T cells. Administration of SCD1 inhibitor or SCD1 knockout in mice synergized with an anti-PD-1 antibody for its antitumor effects in mouse tumor models. High SCD1 expression was observed in one of the non-T cell inflamed subtypes in human colon cancer, and serum SCD1 related fatty acids were correlated with response rates and prognosis of patients with non-small lung cancer following anti-PD-1 antibody treatment.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Although involvement of lipid metabolism in cancer immunity was suggested, the role of fatty acid desaturase stearoyl-CoA desaturase 1 (SCD1) in cancer immune responses has not been investigated. In this study, we attempted to clarify the mechanisms of SCD1 in regulating immune response to cancer cells.

WHAT THIS STUDY ADDS

⇒ Inhibition of SCD1 in cancer cells via suppressing β-catenin signaling and in effector T cells via reducing endoplasmic reticulum stress enhances antitumor T cells through CCL4 recruited dendritic cells and synergizes with antiprogrammed cell death protein 1 (anti-PD-1) antibody. In human cancers, SCD1 is highly expressed in one of the non-T cell inflamed subtypes of colon cancer, and serum SCD1 related free fatty acids are correlated to the responses to anti-PD-1 antibody therapy in patients with non-small cell lung cancer, indicating immunosuppressive functions of SCD1 in patients with cancer.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ SCD1 and the related free fatty acids were found to be attractive targets for diagnosis and therapy to improve current PD-1/PD-L1 inhibitor-based combination immunotherapy.

Conclusions SCD1 expressed in cancer cells and immune cells causes immunoresistant conditions, and its inhibition augments antitumor T cells and therapeutic effects of anti-PD-1 antibody. Therefore, SCD1 is an attractive target for the development of new diagnostic and therapeutic strategies to improve current cancer immunotherapies including immune checkpoint inhibitors.
INTRODUCTION

Cancer immunotherapies, including immune checkpoint inhibitors (ICIs) (eg, with antibodies to programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4) have shown durable clinical effects in patients with various types of cancers. However, their efficacy remains limited to a subset of patients. Analysis of pretreatment tumor biopsy samples from patients treated with checkpoint blockade therapy revealed that patients with pre-existing local antigen-specific CD8+ T cell infiltration (T cell inflamed) that indicates potential induction of T cells for relatively high immunogenic cancers were more likely to show a clinical response. However, most solid tumors have an immunosuppressive tumor microenvironment (TME) without T cell infiltration (non-T cell inflamed), in which cases treatment with anti-PD-1 antibodies alone are ineffective. It is therefore necessary to identify biomarkers to predict clinical effects and therapeutic targets for the development of effective combination therapies by improving the immunosuppressive TME in refractory cases.

Stearoyl-CoA desaturase 1 (SCD1) is the rate-limiting enzyme involved in the synthesis of monounsaturated fatty acids (MUFA) such as palmitoleic acid (16:1 n-7) and oleic acid (18:1 n-9), from saturated fatty acids such as palmitic acid (16:0) and stearic acid (18:0). SCD1 is considered as a potential therapeutic target for cancers because it is expressed at high levels in multiple types of cancers and plays an important role in cancer cell growth by controlling fatty acid metabolism, which is necessary to various cellular functions including maintaining cell membrane components, regulating endoplasmic reticulum (ER) stress signals and oncogenic signals such as the Wnt/β-catenin pathway.

Recently, these SCD1-related signals, such as the Wnt/β-catenin pathway and ER stress signals, have been reported to play an important role in antitumor immune responses. Activation of the β-catenin pathway has been reported to be related to non-T cell infiltrated tumors in various types of human cancers including melanoma, colorectal cancer and liver cancer. Reductions of DC recruiting chemokines, such as C-C motif chemokine ligand 4 (CCL4), or increases of immunosuppressive cytokines such as IL-10, from β-catenin-activated cancer cells was reported as its immunosuppressive mechanism. ER stress signals have also been reported to exert immunomodulatory effects in the TME. For example, nutrient restriction and reactive oxygen species accumulation in the TME cause ER stress in intratumoral T cells, which leads to mitochondrial dysfunction and inhibition of their anticancer effector function.

Although previous studies have investigated the role of SCD1 in the characteristics of cancer cells, the involvement of SCD1 in regulating immune cells, immune cell functions and in antitumor immune responses has not yet been elucidated. In this study, we evaluated the roles of SCD1 in an immunosuppressive TME and antitumor T cell responses and demonstrate that SCD1 and related fatty acids both in cancer cells and in immune cells are attractive targets as biomarkers and therapeutic targets for ICI-based combination immunotherapy.

MATERIALS AND METHODS

Animals and cell culture

Mice were bred at the animal facilities of Keio University, in accordance with the guidelines for animal experimentation. Mice were maintained in a specific-pathogen-free environment on a 12-hour light–dark cycle, with the dark cycle occurring from 20:00 to 08:00. SCD1-global deficient mice with a C57BL/6J background (B6.129-Scd1tm1Ntam/J) were purchased from Jackson Laboratory. The murine colorectal carcinoma cell line (CT26) and murine mammary adenocarcinoma cell line (4T1), murine T cell lymphoma cell line (ELA) and human colon cancer cell line (HT29) were purchased from the American Type Culture Collection. The murine colon adenocarcinoma cell line (MC38) and murine sarcoma cell line (MCA205) and the human melanoma cell lines, 1861mel and 938mel, were obtained from the Surgery Branch of the National Cancer Institute, National Institutes of Health. Human T cells were cultured in AIM-V medium (Thermo Fisher Scientific) containing 10% human-derived AB serum and 300IU/mL recombinant human interleukin-2 (Novartis). Mouse T cells and human and mouse cancer cells were cultured in RPMI 1640 (Thermo Fisher Scientific) containing 10% heat-inactivated fetal bovine serum (FBS), 100U/mL penicillin, and 100µg/mL streptomycin.

PATIENTS

The current study enrolled 57 patients diagnosed with stage II, III and IV colorectal cancer at the Tohoku University Hospital (Sendai, Japan) and 24 patients diagnosed with NSCLC at the Tokyo Medical Center (Tokyo, Japan). PFS and OS were calculated using the Kaplan-Meier method with the use of a log-rank test. PFS was defined as the time from the start of treatment to documented evidence of progressive disease or death. OS was defined as time from treatment initiation to death from any cause. The cut-off used the median. A responder was defined as a patient with ‘complete response’ or ‘partial response’ as determined by RECIST V.1.1 criteria. All participants provided written informed consent before participation in the study.

Tumor-bearing mouse models

C57BL/6, Balb/c and SCD1 KO mice aged 6–8 weeks were inoculated subcutaneously in the flank with 5×10^6 MC38, 5×10^5 CT26, 7×10^5 MCA205, 7×10^5 4T1 cells or 5×10^5 MC38-DsRed cells on day 0. On day 4, mice were treated with vehicle (50% v/v polyethylene glycol 400, 20% v/v propylene glycol, 20% v/v vitamin E, 5% v/v ethanol, 5% w/v polyvinylpyrrolidone) or with 10µg/kg SCD1 inhibitor (A939572) in vehicle. A939572 was purchased...
from APEX BIO. Mice received the vehicle or the inhibitor in vehicle via oral gavage twice daily for 16 days. Mice in the combined therapy group also received anti-PD-1 (J43) or isotype-matched antibody (200 μg/body; Bio X Cell,) on days 4, 7 and 10. For cell depletion, anti-CD8 or isotype antibody (200 μg/body; Bio X Cell) was given intraperitoneally on days 1, 4, 5, 6 and 10. Tumor volume was calculated by direct tumor measurements every 4 days, using the formula: [length × (width)²]/2.

**Samples and sample preparation for gas chromatography-mass spectrometry (GC-MS)**

To 20 μL of serum, 0.3 mL of PBS containing an internal standard (100 ng of margaric acid) was added and mixed with vortex mixer. Draining lymph nodes cells (1×10⁶ cells) and mouse cancer cell lines (1×10⁶ cells) were sonicated with 0.3 mL of PBS containing an internal standard. Free fatty acids were extracted using SOLUTE SLE + column and dichloromethane. The organic fractions were dried under nitrogen stream. Tumor tissue sample were grounded using a multibead shoker (MB755U, Yasui Kikai) with a frozen disruption device, and 1 mL methanol containing an internal standard was added. After addition of 0.5 mL of deionized water and 0.8 mL chloroform, the mixture was centrifuged at 20000×g for 15 min at 4°C. The lower organic layer of the sample was collected and dried under nitrogen stream. The residue was dissolved in 5 μL of pyridine and 30 μL of the reagent BSTFA+TMCS (99:1) (TS-38831, Thermo Fisher Scientific) for trimethylsilylation. The derivatization reaction was performed for 30 min at 40°C.

**GC-MS analyses**

GC-MS analysis was performed on a Shimadzu GC-MS QP2010 Ultra equiped with an AOC20i autoinjector and Rtx-5MS column (30m, 0.25mm, 0.25μm df) in the 70eV electron ionization mode. The oven temperature program was as follows: 150°C for 1 min, 20°C/min to 250°C, 5°C/min to 280°C, hold 5 min. then 20°C/min to 330°C, hold for 3 min where the temperature was maintained for 10 min. The carrier gas was helium with a constant flow speed of 42.0 cm/sec. One microliter was injected in 5:1 split ratio with an injector temperature of 250°C, MS interface temperature was held at 280°C. Selected ion monitoring for quantification was performed by recording the ions at m/z 311.20 for palmitoleic acid-trimethylsilyl derivative, m/z 313.20 for palmitic acid-trimethylsilyl derivative m/z 327.20 for margaric acid-trimethylsilyl derivative, m/z 339.20 for oleic acid-trimethylsilyl derivative, and m/z 341.20 for stearic acid-trimethylsilyl derivative, respectively.

**RESULTS**

**The SCD1 inhibition enhances antitumor T cells through recruiting DCs into tumors**

In order to clarify the role of fatty acid metabolic enzyme SCD1 in the cancer-related immune response, we evaluated the immunologic antitumor effects of SCD1 inhibition and its mechanism using C57BL/6 and Balb/C mice implanted with four different types of syngeneic murine tumors, including MC38 colon cancer cells, CT26 colon cancer cells, MCA205 sarcoma cells and 4T1 breast cancer cells. SCD1 gene expression, enzymatic activity and direct biological effects of the SCD1 inhibitor in all these cell lines are shown in online supplemental figure 1A–C. Oral administration of the SCD1 inhibitor A995972 inhibited fatty acid desaturation, as shown by the decreased ratios of palmitoleic acid/palmatic acid and oleic acid/stearic acid in the tumor, draining lymph nodes and sera of those tumor-bearing mice (figure 1A) and significantly inhibited the growth of all four tumors (figure 1B).

That antitumor effect of inhibiting SCD1 was abrogated by the depletion of CD8+ T cells in MC38-bearing mice (figure 1C), indicating the involvement of CD8+ T cells in the in vivo antitumor effects of the SCD1 inhibitor. SCD1 inhibition significantly enhanced the induction of tumor antigen specific CD8+ T cells in tumors and draining lymph nodes in MC38 and MCA 205 bearing mice when evaluated by the interferon (IFN)-γ secreted from tumor antigen gp70-specific T cells (figure 1D) and in CT26-bearing mice when evaluated by gp70/H-2Ld-tetramer staining (figure 1E).

Administration of the SCD1 inhibitor also increased the infiltration of CD8+ T cells into tumors in all four tumor models when analyzed by gene expression analysis by qPCR, flow cytometry and immunohistochemical analyses (figure 2A, online supplemental figure 2 and 3A left panel), although regulatory T cells were not significantly changed (online supplemental figure 3B,C). The expression of stimulatory and inhibitory coceptors of T cells, including 4-1BB, PD-1, TIGIT and Lag3, was also enhanced in these tumor-infiltrating CD8+ T cells by treatment with the SCD1 inhibitor, suggesting the activation and subsequent exhaustion of tumor antigen-specific T cells in tumors (figure 2B, online supplemental figure 3A right panel).

The accumulation of DCs in tumors is known to be important for the induction and effector function of antitumor T cells. In all four tumor models, the tumor-infiltrating CD45+CD11c+ DCs were also increased following administration of the SCD1 inhibitor (figure 2C). The expression of CD80, CD83 and CD86 was increased in DCs that infiltrated in CT26 tumors, suggesting the maturation of DCs following SCD1 inhibition (online supplemental figure 3D). Expression of the chemokine CCL4, which is important for recruiting DCs into tumors, was significantly increased by SCD1 inhibition (figure 2D), accompanied by the decreased expression of activating transcription factor 3 (ATF3) (figure 2E), a transcription factor that inhibits CCL4 expression. These results suggest that SCD1 inhibition enhances the production of CCL4 in tumor tissues via ATF3 inhibition, which in turn promotes the induction and effector function of tumor antigen specific CD8+ T cells through the accumulation and maturation of DCs in tumors.
The SCD1 inhibition enhances CCL4 production in tumor cells via suppressing Wnt/β-catenin signaling

Tumor cells are reported to be one of the major sources of CCL4 in tumor tissues. We then evaluated production of CCL4 by various tumor cells, including murine tumor cell lines (MC38, CT26, and 4T1), a human cancer cell...

Lines (HT29 colon cancer and 1861mel melanoma) in vitro, and attempted to clarify the mechanisms for the inhibition of CCL4 production in tumor cells by SCD1 inhibition. The SCD1 inhibitor significantly enhanced CCL4 gene expression in these tumor cells, which was canceled by the addition of oleic acid, an unsaturated fatty acid produced by SCD1, indicating that oleic acid is involved in the regulation of CCL4 expression in these tumor cells (figure 3A). Knockdown of SCD1 by siRNAs also enhanced CCL4 gene expression (figure 3B) accompanied by reduction of ATF3 expression (figure 3C) and knockdown of ATF3 enhanced the expression of CCL4 (figure 3D) as previously reported.24

Since it was reported that SCD1 expression and activity were bidirectionally regulated by the Wnt/β-catenin signaling16,17 and that activation of the Wnt/β-catenin signaling inhibited CCL4 production via activation of ATF3 in human melanoma cells,18 we evaluated whether SCD1 regulates CCL4 production via β-catenin-ATF3 axis in these tumor cell lines. The SCD1 inhibitor reduced whole and nuclear β-catenin expression (figure 3E), and it was rescued by the addition of oleic acid (figure 3E), suggesting that oleic acid is involved in enhancing β-catenin signaling. Oleic acid was previously reported to stabilize β-catenin levels in cancer cells by preventing its degradation by proteasomes.25 Knockdown of β-catenin gene in these tumor cells or overexpression of mutant β-catenin gene in human melanoma cell line 938-mel expressing low β-catenin gene19 also regulated SCD1 expression in a negative or positive manner in the tumor cell lines (online supplemental figure 4A,B), indicating that SCD1 and β-catenin regulate their expression in a bidirectional manner. Knockdown (figure 3F) or overexpression (figure 3G) of β-catenin also enhanced or suppressed CCL4 production, respectively, accompanied by the inverse expression of ATF3 (figure 3H,I). These results indicate that bidirectional regulation between SCD1 and β-catenin signaling and downstream ATF3 control CCL4 production in the tumor cells.

We then confirmed the in vivo effect of SCD1 inhibition on CCL4 production in tumor cells using mice implanted

**Figure 2** Inhibition of SCD1 enhances the infiltration of CD8+ T cells and DCs into tumors via production of CCL4. C57BL/6 mice bearing MC38 or MCA205 tumors and Balb/c mice bearing CT26 or 4T1 tumors were treated with a SCD inhibitor (SCDinh) or with vehicle only (mock). Tumors were excised on day 20. (A) Analysis of tumor-infiltrating CD8+ T cells by qPCR, flow cytometry, immunostaining and image analysis (n=5). (B) Percentages of 4-1BB+, PD-1+, TIGIT+ and Lag3+ CD8+ T cells in tumors analyzed by flow cytometry in C57BL/6-MC38 model (n=5). (C) Absolute numbers of CD45+ CD11c+ cells analyzed by flow cytometry (n=5). (D, E) Ccl4 and Atf3 gene expression evaluated by real-time RT-PCR (n=5). *P<0.05, **P<0.01. N.D., not determined. Data are expressed as means ± SD.
Figure 3  SCD1 regulates CCL4 production via β-catenin in tumor cells. (A) Mouse (MC38, CT26 and 4T1) and human (HT29 and 1861mel) cancer cells were cultured in RPMI medium containing 2% serum supplemented with a SCD inhibitor (SCDinh), with SCDinh + oleic acid (SCDinh + OA) or with dimethylsulfoxide (DMSO). Total RNA was extracted and CCL4 mRNA was evaluated using real-time RT-PCR. (B, C) Cancer cells were transfected with small interfering RNA (siRNA)-SCD1 or with siRNA-control (si-negative) after which CCL4 (B) and ATF3 (C) mRNA levels were evaluated by real-time RT-PCR at 48 h post-transfection. (D) Cancer cells were transfected with siRNA-ATF3 or with siRNA-control after which mRNA levels were evaluated by real-time RT-PCR at 48 h post-transfection. (E) Whole cell and nuclear β-catenin protein levels were measured by western blot; GAPDH and lamin A/C were used as controls. (F–I) Knockdown (F, H) or overexpression (G, I) of β-catenin in mouse and human cancer cell lines. Cancer cells were transfected with siRNA-β-catenin or with si-negative after which CCL4 (F) and ATF3 (H) mRNA levels were evaluated by real-time RT-PCR at 48 h post-transfection. CCL4 (G) and ATF3 (I) gene expression in a human melanoma cell line (938mel) overexpressing β-catenin. Data are expressed as means ± SD (n=3). *P<0.05, **P<0.01. N.D., not determined. O.E., over-expressing.

with DsRed-labeled MC38 tumors. An increase of CCL4 along with a decrease of ATF3 was observed in DsRed+ MC38 cells isolated from tumors of mice treated with the SCD1 inhibitor (figure 4A, upper panel). These results suggest that SCD1 inhibition acts directly on tumor cells to enhance the production of CCL4 via the β-catenin/ATF3 axis, which results in the enhanced recruitment of DCs into tumors and the subsequent CD8+ T cell induction and accumulation.

We also evaluated the possible roles of SCD1 in the tumor immune microenvironment in human colon cancer. Transcriptome analysis of 57 advanced colon cancer samples revealed that one of the non-T cell...
inflamed subtypes (group 4) had low expression of CD8a, IFNG and GZMB with high expression of SCD1 and CTNNB1 (β-catenin) and its downstream molecules including VEGFA and TCF71. In contrast, the T cell inflamed subtype (group 1) showed high expression of CD8a and CCL4 and low expression of CTNNB1 and SCD1 (figure 4B,C). This subtype also expressed molecules related to DCs with cross-priming ability, including CD11b1 and XCR1, and the DC recruiting chemokine CCL4 (figure 4C). SCD1 expression was significantly correlated with β-catenin expression that was inversely correlated with CD8a and XCR1 (figure 4D) as previously reported in human melanoma.18 These results indicate that the SCD1/β-catenin/ CCL4 pathway may also be involved in the non-T cell inflamed subtype of human colon cancer.

The SCD1 inhibition enhances CCL4 expression in T cells via reducing ER stress

In DsRed-labeled MC38-bearing mice, the expression of CCL4 was found to be significantly higher in tumor-infiltrating CD8+ T cells on a per cell basis than in tumor cells, and it was increased by treatment with the SCD1 inhibitor (figure 4A, lower panel). In CD8+ T cells, the expression of β-catenin and its downstream genes were relatively low at basal levels, and treatment with SCD1 inhibitors did not alter the β-catenin-related genes such as Tcf7 and Vегाळ (online supplemental figure 5). ATF3, which regulates CCL4 expression, was reported to be induced by ER stress26 that is regulated by SCD1.19 Thus, we evaluated the status of ER stress in the tumor-infiltrating CD8+ T cells and found that administration of the SCD1 inhibitor reduced the expression of ATF3 (figure 4A, lower panel) accompanied by a reduction of ER stress-related molecules such as ratio of spliced Xbp1 (sXbp1; active isoform)/unspliced Xbp1 (uXbp1), Ddit3, Hspa5 (BiP), Atf4 and Atf6 (figure 4E lower panel), indicating that SCD1 inhibition reduced various ER stress pathways in CD8+ T cells. In contrast, SCD1 inhibition enhanced ER stress in MC38 tumor cells as previously reported10 (figure 4E upper panel), indicating that SCD1 had opposite in vivo effects on ER stress in tumor cells and in CD8+ T cells in mice treated with the SCD1 inhibitor. Therefore, different mechanisms through β-catenin or ER stress are employed for the SCD1 dependent regulation of CCL4 in cancer cells and in CD8+ T cells. These results indicate that in addition to enhancing CCL4 production in tumor cells, the SCD1 inhibitor also induce the high production of CCL4 by tumor infiltrating CD8+ T cells through the reduction of ER stress, suggesting that triggering of DC recruitment and subsequent T cell induction by CCL4 derived from tumor cells, and further amplification of antitumor T cell responses by CCL4 derived from tumor infiltrating CD8+ T cells.

The SCD1 inhibitor acts directly on CD8+ T cells and DCs to enhance their functions

We then tested whether the inhibition of SCD1 acts directly on CD8+ T cells in vitro. CCL4 expression was increased along with a decrease of ATF3 in human peripheral blood and in mouse splenic CD8+ T cells treated in vitro with the SCD1 inhibitor (figure 5A). Similarly, higher CCL4 and lower ATF3 expression in CD8+ T cells obtained from spleens of SCD1 knockout (KO) mice were observed than those in CD8+ T cells from wild-type (WT) mice (figure 5A). Furthermore, as shown in the DsRed-MC38 model (figure 4E, lower panel), a ratio of sXbp1/uXbp1 was significantly lower in CD8+ T cells of SCD1 KO mice, indicating lower levels of ER stress in SCD1 negative CD8+ T cells (figure 5B). Proliferation of these human and mouse CD8+ T cells was significantly enhanced by SCD1 inhibition or by SCD1 KO (figure 5C). To further clarify the causal relationship between ER stress and CCL4 production, we tested the effect of ER stress inducer tunicamycin on human CD8+ T cells in vitro and found that it significantly reduced CCL4 production (figure 5D), indicating CCL4 production may also be regulated by ER stress in CD8+ T cells. Since SCD1 is also expressed in human DCs (online supplemental figure 6), we also analyzed the direct effect of the SCD1 inhibitor on human DCs. In vitro treatment of human monocyte derived DCs with the SCD1 inhibitor significantly increased the production of tumor necrosis factor (TNF)-α in the presence of lipopolysaccharide (figure 5E) and enhanced allogeneic T cells to produce IFN-γ (figure 5F). These results indicate that the SCD1 inhibitor acts directly on human CD8+ T cells and DCs and enhances their functions.

SCD1 is a potential target to enhance the antitumor effects of an anti-PD-1 antibody

Based on the increase of PD-1 positive CD8+ T cells in tumors in SCD1 inhibitor-treated mice (figure 2B, online supplemental figure 4A, right panel), we evaluated the antitumor effect of a combination of the SCD1 inhibitor and an anti-PD-1 antibody, and synergistic antitumor effects were observed in four tumor models. Some of the mice had complete tumor regression in MCA205, CT26 and 4T1 tumor models (figure 6A). Over-expression of SCD1 by lentiviral cDNA transduction resulted in significant increase of tumor growth compared to mock transfected MC38 (figure 6B), although anti-PD-1 antibody was still effective. Conversely, SCD1 knockdown MC38 by shRNA showed reduced tumor growth, although not significantly possible due to the redundant expression of SCD isoforms SCD2-4 (online supplemental figure 7). With the results of the increased CCL4 production by SCD1 knockdown tumor cells (figure 3B), these results suggested the immunoresistant role of SCD1 in tumor cells. In addition, the antitumor effect of the anti-PD-1 antibody was significantly higher in SCD1 KO mice accompanied by enhanced gp70-specific CD8+ T cell induction compared with WT mice (figure 6CD). With the results of in vitro direct enhancing effects of the SCD1 inhibitor on T cells and DCs (figure 5C-F), these results indicate the immunosuppressive roles of SCD1 in host immune cells. Altogether, SCD1 inhibitors may be useful for combination immunotherapy with anti-PD-1/PD-L1 antibodies by acting on both cancer cells and immune cells.
SCD1 and related free fatty acids are potential biomarkers to predict PD-1 antibody responses

We also investigated the possible roles of SCD1 and related metabolites as biomarkers for immunotherapy. In addition to the relatively high expression level of SCD1 in non-T cell inflamed tumors that may not be sensitive to anti-PD-1 antibody therapy (figure 4B–D), fatty acid metabolites generated by SCD1 might be biomarkers for T cell dependent immunotherapy. We then evaluated SCD1-related free fatty acids at baseline (before the therapy) in the sera of non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 antibody therapy and found that lower ratio of palmitoleic/palmitic acid and lower levels of serum palmitoleic acid and palmitic acid at baseline were significantly correlated with better responses and prognosis including progression-free survival (PFS) and overall survival (OS) following anti-PD-1 antibody treatment, although the ratio of oleic acid/stearic acid was not significantly correlated with the clinical outcomes (figure 7, online supplemental figure 8A–C). These results indicate that serum palmitoleic acid and palmitic acid regulated by SCD1 could be predictive biomarkers for immunotherapy.

DISCUSSION

The antitumor effects of PD-1/PD-L1 inhibitors alone are limited, and there is thus an urgent need to identify biomarkers to predict responses and therapeutic targets to develop more effective combination immunotherapies. In this study, we demonstrated that SCD1 in tumor cells suppresses antitumor CD8+ T cells through decreased numbers of DCs in tumors via the reduced level of DC-recruiting CCL4 caused by activation of the β-catenin pathway. In addition, we also showed that SCD1 was involved in the direct suppression of functions of CD8+ T cells and DCs, particularly the suppression of CCL4 production by CD8+ T cells through augmenting...
Open access

ER stress. Finally, we showed that SCD1 was an attractive target for combination immunotherapy because treatment with a SCD1 inhibitor augmented the antitumor effects of anti-PD-1 antibody, and SCD1 was a potential biomarker as suggested by high expression of SCD1 in non-T cell inflamed human colon cancers and the correlation of serum SCD1-related fatty acids with the responses to anti-PD-1 antibody in NSCLC patients.

Chemokines such as CCL4 have been reported to be important factors for developing a T cell-inflamed TME by recruiting DCs into tumors, which subsequently induce tumor antigen-specific CD8+ T cells and support tumor-infiltrating CD8+ effector T cells.6 In this study, we revealed two different mechanisms by which SCD1 inhibition enhances the production of CCL4 in cancer cells or CD8+ T cells. In cancer cells, SCD1 was found to inhibit the production of CCL4 that is negatively regulated by activated ATF3 through β-catenin signaling that is partly regulated by unsaturated fatty acids such as oleic acid and palmitoleic acid produced by SCD1.18 24 25 27 28 We have

Figure 6  Inhibition of SCD1 enhances the therapeutic effect of anti-PD-1 antibodies. (A) Mice bearing MC38, MCA205, CT26 and 4T1 tumors were treated with a SCD1 inhibitor (SCDinh; 10 mg/kg) or with vehicle and with an anti-PD-1 antibody (200 µg /mouse) or an isotype-matched antibody. Tumor-growth curves for individual mice (left 4 panels) and average tumor volumes (right panel) (means ± SD; n=5). (B) C57BL/6 mice bearing vector control MC38 (MC38 mock) or SCD1 over-expressed MC38 tumors were treated with an anti-PD-1 (200 µg /mouse) or an isotype-matched antibody. (C) Antigen (gp70)-specific T-cell induction in SCD1 KO mice bearing MC38 tumors. (D) Wild-type (WT) or SCD1 KO mice bearing MC38 tumors were treated with an anti-PD-1 (200 µg /mouse) or an isotype-matched antibody.

shown that SCD1 inhibition suppresses the expression of β-catenin and its downstream molecule, ATF3, and enhances the expression of CCL4 in mouse and human cancer cells and that SCD1 and the β-catenin pathway are positively correlated in patients with colorectal cancer.

In line with our findings, previous reports showed the positive relationship between SCD1 and Wnt/β-catenin signaling in human hepatocellular carcinoma and clear cell renal cell carcinoma cells. MUFA (palmitoleic acid) synthesized by SCD1 is ligated to Wnt protein, leading to its activation of β-catenin signaling.27–29 Oleic acid produced by SCD1 and its downstream metabolites, polyunsaturated 18-carbon fatty acids, stabilize β-catenin in cancer cells by preventing its proteasomal degradation.25 These observations suggest that SCD1 inhibition suppresses Wnt/β-catenin signaling in cancer cells through multiple mechanisms.

Consistent with previous reports,17 we have also shown that SCD1 works as a downstream of β-catenin signaling. Therefore, SCD1 and β-catenin bidirectionally regulate the immunoresistance mechanism. The inhibition of SCD1 depletes oleic acid, which is the main component of the cell membrane, leading to cancer cell death10 that may also enhance the antitumor immune response via releasing tumor antigens to DCs. There are currently no clinically approved Wnt/β-catenin inhibitors due to their relatively poor specific activities and adverse effects. SCD1 inhibitors may be useful to restore antitumor immune responses for cancers with activated β-catenin signaling.

In contrast to cancer cells, SCD1 inhibited the production of CCL4 by CD8+ T cells through increased ATF3 activated by ER stress. We showed that SCD1 inhibition in

Figure 7 SCD1-related free fatty acids and ratio are potential biomarkers to predict PD-1 antibody responses and prognosis. (A) Pretreatment serum levels of palmitic and palmitoleic acid and ratio of palmitoleic/palmitic acid from NSCLC patients who subsequently did (Responder, n=6) or did not (Non-responder, n=18) respond to anti-PD-1 antibody treatment. (B, C) Kaplan–Meier analyses of NSCLC patients before anti-PD-1 antibody treatment. Kaplan–Meier curve of high (n=12) and low (n=12) palmitic acid, palmitoleic acid and palmitoleic/palmitic acid ratio in the serum of PFS patients (B) (HR 0.34, 95% CI 0.13 to 0.85; HR 0.32, 95% CI 0.13 to 0.77; HR 0.35, 95% CI 0.14 to 0.87, respectively) or OS patients (C) (HR 0.34, 95% CI 0.12 to 0.94; HR 0.25, 95% CI 0.09 to 0.69; HR 0.25, 95% CI 0.09 to 0.71, respectively). The threshold between high and low was median (palmitic acid; 1.33, palmitoleic acid; 0.10, palmitoleic/palmitic acid ratio; 0.10).
CD8+ T cells reduced ER stress as shown by the decreased ratio of sXbp1/uXbp1 and other related molecules and increased CCL4 expression through ATF3 decrease in vitro and in vivo, without affecting β-catenin signaling. ATF3 has been previously reported to be regulated by ER stress and by β-catenin signaling. We showed that the SCD1 inhibitor might act directly on CD8+ T cells and DCs to enhance their functions with the reduced ER stress. It was reported that DC-intrinsic XBP1 promotes ovarian cancer progression and that silencing XBP1 in DCs enhances T cell antitumor immunity. XBP1 also enhances the expression of T cell exhaustion markers such as PD-1, TIM-3, and Lag3 in CD8+ T cells during infection, and the activation of XBP1 in T cells was associated with the suppression of mitochondrial activity and reduced IFNγ, TNF-α and granzyme B production. Therefore, functions of immune cells, including CCL4 production, are regulated by ER stress, which can be a therapeutic target.

Additional lipid metabolism may be involved in the mechanisms by which SCD1 might suppress the functions of T cells or DCs. We observed decreased expression levels of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN) in SCD1 inhibitor-treated mouse CD8+ T cells (online supplemental figure 9A,B) as previously reported. It was reported that fatty acid syntheses via ACC and FASN are involved in abnormal fatty acid accumulation and suppress mitochondrial function in mouse DCs. Large amounts of saturated fatty acids have been reported to enhance ER stress in normal human and mouse cells such as muscle cells and renal epithelial cells through activation of the ER stress sensors IRE1α and PERK. Although SCD1 inhibition suppress conversion of saturated fatty acids to unsaturated fatty acids, decrease of total fatty acids through decreased ACC and FASN, which were observed in CD8+ T cells treated with the SCD1 inhibitor, might result in the decreased ER stress in CD8+ T cells following SCD1 inhibitor treatment and enhanced T cell responses. These lipid metabolic enzymes are suppressed by SCD1 inhibition, possibly leading to enhanced antitumor immune responses. It has recently been reported that imbalance between unsaturated and saturated fatty acids by SCD1 activation and its downstream lipid metabolisms is involved in the tumor growth during calorie restriction. SCD1 inhibition may also activate CD8+ T cells through the change of cholesterol metabolism. Increase of intracellular cholesterol via inhibition of acetyl-coenzyme A acetyltransferase 1 (ACAT1) that uses oleic acid produced by SCD1 as a substrate for the esterification of cholesterol. ACAT1 inhibition was reported to activate the antitumor activity of CD8+ T cells.

The mechanisms of opposite effects on ER stress in tumor cells and CD8+ T cells clearly observed in vivo following administration of the SCD1 inhibitor were not completely understood. It has been reported that SCD1 inhibition increases ER stress partly due to accumulation of SCD1 substrates such as palmitic acids and stearic acids, leading cell death of cancer cells. Different fatty acid metabolisms among cell types have been reported, including different effects of saturated fatty acids, utility of MUFA, and expression of alternative fatty acid desaturase. In this study, decreased sXbp1/uXbp1 ratio in CD8+ T cells isolated from SCD1 KO mice and decrease of CCL4 production by in vitro treatment of CD8+ T cells with ER stress inducer tunicamycin suggest that SCD1 inhibition promoted CCL4 production partly via decreased ER stress in CD8+ T cells. In addition, improved conditions in immune-environment of tumors and lymph nodes may also be one of the mechanisms for the decrease of ER stress in CD8+ T cells in vivo following the SCD1 inhibitor administration.

In this study, the SCD1 inhibitor enhanced CCL4 production by cancer cells and by tumor-infiltrating CD8+ T cells. Higher production of CCL4 by tumor-infiltrating T cells was observed compared with cancer cells on a per-cell basis. CD8+ T cells themselves were reported to promote the recruitment of activated CD8+ T cells into tumors by recruiting various DCs via CCL3, CCL4 and XCL1. CCL4 from tumor cells may be essential in triggering the early phase of DC recruitment, while CCL4 from tumor-infiltrating CD8+ cells may further amplify the accumulation of DCs and T cells later as a positive feedback system for antitumor T cell responses.

Biomarkers for predicting responses to immune checkpoint inhibitors such as cancer gene alterations and immune responses have been extensively investigated using patients’ tumor and blood samples. In this study, we demonstrated that palmitic and palmitoleic acid levels and ratio of palmitoleic/palmitic acid in the sera of NSCLC patients at baseline were inversely correlated with the responses and prognosis including DFS and OS of patients treated with anti-PD-1 antibody and could be predictive biomarkers for PD-1/PD-L1 based immunotherapy. It is consistent with the negative roles of SCD1 shown in our mouse tumor models. It may be a reflection of SCD1 expression in cancer cells and immune cells in tumors. SCD1 was highly expressed in non-T cell inflamed subtype in colon cancer, which are likely to be resistant to anti-PD-1 antibody. Previous studies of patients with diabetes showed a correlation between the serum SCD1-related fatty acid ratio and SCD1 gene expression in tissues. Although further study is needed to confirm those biomarker roles in patients with various types of cancers, SCD1-related free fatty acids may be potential biomarkers for cancer immune therapies. Interestingly, no significant correlation between the ratio of serum oleic acid and stearic acid and clinical outcomes was observed in this study possibly due to the involvement of additional systemic fatty acid metabolisms of serum oleic acid and stearic acid in patients, regardless of possible changes of their free fatty acids in tumor micro-environments as shown in mouse models. In addition, low levels of palmitic acid and stearic acid, substrates of SCD1 appeared to correlate with clinical outcomes, indicating...
fatty acid synthesis via ACC and FASN in the downstream of SCD1 may also be involved in the immunosuppressive conditions in patients with cancer as shown in our mouse models in this study. Further mechanistic investigation is needed for their precise mechanisms. Altogether, we have shown in this study that SCD1 expressed in cancer cells and immune cells such as CD8+ T cells and DCs is involved in the immune-resistant mechanisms for immune checkpoint blockade and is an attractive target for the development of new diagnostic and therapeutic strategies for effective cancer immunotherapy.

Author affiliations
1Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
2Division of Anatomical Science, Department of Functional Morphology, Nihon University School of Medicine, Tokyo, Japan
3Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan
4Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
5Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan
6National Hospital Organisation Tokyo Medical Center, Tokyo, Japan
7Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan
8Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan
9Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan
10DNA Chip Research Inc, Tokyo, Japan
11Department of Immunology, International University of Health and Welfare, Chiba, Japan

Acknowledgements We would like to thank Miyuki Saito for technical assistance and Misako Horikawa, Ryoko Suzuki and Naoko Tomita for preparation of the manuscript.

Contributors YKat, TY and YKaw conceived and designed the study. YKat, TY, AK, TI, KM, DK, SO, RM, MS and YKaw acquired, analyzed or interpreted the data. RS, YY, YO, KO, ST and CI collected clinical specimens. YKat, TY and YKaw drafted or substantially revised the work. YKaw is responsible for the overall content as the guarantor.

Funding This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (26221005, 20H03534, 21H02785, 18K03093, 15K09783, and 21K15602); the Grants from the Japan Agency for Medical Research and Development (AMED) (P-CREATE) (20km106306h0005); Japan Science and Technology Agency (JST) Exploratory Research for Advanced Technology (ERATO) Suematsu gas biology project; a grant from Kobayashi Foundation for Cancer Research; GSK Japan Research Grant 2021; Nihon University Research Grant-in-aid for EarlyCareer Scientists (2021).

Disclaimer The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The study using human specimens was approved by Keio University School of Medicine Ethics Committee, and all participants provided written informed consent before participation in the study (No. 20110159). Participants gave informed consent to participate in the study before taking part. All animal studies were reviewed and approved by the Keio University Institutional Animal Care and Use Committee (No. 4062). Recombinant DNA experiments were reviewed and approved by Genetic Modification Safety Committee, Keio University School of Medicine (No. 25-014-13).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Yuki Katoh http://orcid.org/0000-0002-7467-3377
Tomonori Yaguchi http://orcid.org/0000-0002-2904-9030
Yutaka Kawakami http://orcid.org/0000-0002-0036-1186

REFERENCES


